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Endothelium in embryonic hematopoietic tissues
generates hematopoietic stem/progenitor cells;
however, it is unknown how its unique potential is
specified. We show that transcription factor Scl/
Tal1 is essential for both establishing the hematopoi-
etic transcriptional program in hemogenic endothe-
lium and preventing its misspecification to a cardio-
myogenic fate. Scl/ embryos activated a cardiac
transcriptional program in yolk sac endothelium,
leading to the emergence of CD31+Pdgfra+ cardio-
genic precursors that generated spontaneously
beating cardiomyocytes. Ectopic cardiogenesis
was also observed in Scl/ hearts, where the disor-
ganized endocardium precociously differentiated
into cardiomyocytes. Induction of mosaic deletion
of Scl in Sclfl/flRosa26Cre-ERT2 embryos revealed
a cell-intrinsic, temporal requirement for Scl to pre-
vent cardiomyogenesis from endothelium. Scl/
endothelium also upregulated the expression of
Wnt antagonists, which promoted rapid cardiomyo-
cyte differentiation of ectopic cardiogenic cells.
These results reveal unexpected plasticity in embry-
onic endothelium such that loss of a single master
regulator can induce ectopic cardiomyogenesis
from endothelial cells.590 Cell 150, 590–605, August 3, 2012 ª2012 Elsevier Inc.INTRODUCTION
The hematopoietic and cardiovascular systems are the first
organ systems to develop due to their essential functions in sup-
porting the embryo. Blood cells, the heart, and the vasculature
are generated from lateral plate mesoderm (Fehling et al.,
2003; Kattman et al., 2006) in a highly coordinated process
that ultimately facilitates the circulation of blood cells in the
endothelium-lined blood vessels. The high mortality from blood
and cardiovascular diseases warrants studies to define the
mechanisms that facilitate the establishment and regeneration
of these cell types. However, the road map for generating
stem/progenitor cells for the different mesodermal lineages is
lacking, limiting our ability to derive these cells for clinical use.
It has now been established that the embryonic endothelium
not only is a conduit for blood, but also serves as a source of
hematopoietic stem/progenitor cells (HS/PCs) (Bertrand et al.,
2010; Boisset et al., 2010; Chen et al., 2009; Eilken et al., 2009;
Kissa and Herbomel, 2010; Lancrin et al., 2009; Zovein et al.,
2008). This unique ‘‘hemogenic endothelium’’ is found during
a defined developmental window in intra- and extraembryonic
tissues that generate HS/PCs, including the para-aortic splanch-
nopleura/aorta-gonad-mesonephros (pSP/AGM) region, the
yolk sac, and the placenta (Chen et al., 2009; Rhodes et al.,
2008; Zovein et al., 2008). However, the mechanisms that
govern hemogenic competence in the endothelium are poorly
understood.
Fate choice toward cardiovascular and hematopoietic line-
ages begins when gastrulating cells invaginate through the
Figure 1. Scl Establishes Hemogenic Endothelium in the Yolk Sac
(A) Analysis of E 9.25 Scl/ embryos documented lack of primitive red cells (arrow) and (B) CD41+cKit+ HS/PCs.
(B) Sorting strategy used to isolate endothelial cells from control and Scl/ yolk sacs (YSs). Cells lacking hematopoietic markers CD41 (green boxes), CD45, and
Ter119 but expressing CD31+ (blue boxes) were subjected to gene expression analysis.
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primitive streak; timing and localization of ingression dictates
which morphogens nascent mesodermal cells encounter while
migrating to their destination (Kinder et al., 2001). Morphogens
that regulate mesodermal fate choice include Wnt, Fgf, TGFb,
and BMP (Nostro et al., 2008; Simo˜es et al., 2011). Combinations
of these morphogens and their relative levels promote the
patterning of the mesoderm to different cardiovascular and
hematopoietic fates (Kattman et al., 2006, 2011; Simo˜es
et al., 2011).
The bHLH transcription factor Scl/Tal1 is a candidate tran-
scription factor responsible for specifying hemogenic endothe-
lium from mesoderm (Lancrin et al., 2009). Scl/ embryos die
by E 9.5 of mouse development due to absence of blood and
poorly remodeled vasculature (Shivdasani et al., 1995; Visvader
et al., 1998). The requirement for Scl to specify the hematopoietic
fate is limited to a narrow window; conditional deletion of
Scl using the hematoendothelial-specific Tie2/Tek Cre strain or
the interferon-inducibleMx Cre strain do not disrupt the genera-
tion or maintenance of HS/PC pool, although erythropoiesis
and megakaryopoiesis are compromised (Mikkola et al.,
2003b; Schlaeger et al., 2005). Recent studies revealed that
Scl becomes dispensable for HS/PC maintenance due to func-
tional redundancy with a related bHLH factor Lyl1 (Souroullas
et al., 2009).
Despite the critical role for Scl in the establishment of the
hematopoietic system, little is known about how it generates
HS/PCs. Chromatin immunoprecipitation (ChIP)-sequencing in
embryonic HS/PCs and erythroid cells revealed widespread
binding of Scl and other hematopoietic transcription across
thousands of genes, many of which regulate hematopoietic
stem cell (HSC) development or maintenance (Kassouf et al.,
2010; Wilson et al., 2010). However, these genome-wide binding
studies have provided little information about the genes that
depend on each of these factors for their expression.
Here we show that Scl establishes hemogenic endothelium by
activating transcription factors required for HS/PC emergence
and self-renewal. Moreover, our studies revealed an unexpected
repressive role for Scl, as loss of Scl resulted in the generation of
ectopic cardiomyocytes in yolk sac vasculature and the endo-
cardium. These results uncover remarkable developmental
plasticity in embryonic vasculature and identify Scl as a key
determinant of endothelial fate choice.
RESULTS
Scl Establishes Hemogenic Competence in Endothelium
Embryos devoid of Scl lack embryonic red cells and HS/PCs in
all hematopoietic tissues (Figures 1A and 1B; Figure S1A avail-
able online), providing an ideal in vivo model to study the estab-
lishment of the hematopoietic system. To determine which(C) Heat maps represent the relative expression and fold change of hematopoie
(>1.5-fold, p < 0.05) inScl/ versus control YS endothelium; expression in control
from differentially expressed genes are listed.
(D) qPCR for hematopoietic TFs on E 9.25 unfractionated YSs; mean of four biol
(E) IF for Scl-dependent HS/PCmarker CD41 (n = 3); insets are highermagnificatio
error bars represent SEM.
See also Figure S1 and Tables S1A and S2A.
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yolk sac by Scl, we performed microarray analysis on Scl/
and control CD31+ cells that were depleted of hematopoietic
cells and compared them to CD41+cKit+ HS/PCs from control
yolk sacs. Gene ontology enrichment analysis of the 1,295 differ-
entially expressed genes (Table S1a) downregulated in Scl/
endothelium (>1.5-fold, p < 0.05) revealed a robust Scl-depen-
dent hematopoietic transcriptional program in yolk sac endothe-
lium. These genes included transcription factors regulating HSC
development (Runx1, cMyb, Fli1), self-renewal (Etv6/Tel, Izkf1/
Ikaros, Erg, Gfi1), and differentiation (Gata1 and Gfi1b), as well
as surface proteins expressed on hematopoietic cells (Itga2b/
CD41, a marker of nascent HS/PCs (Bertrand et al., 2005;
Mikkola et al., 2003a) and the panhematopoietic marker Ptprc/
CD45) (Figure 1C). Quantitative PCR (qPCR) on yolk sacs verified
Scl dependence of key hematopoietic transcription factors (Fig-
ure 1D). Immunofluorescence (IF) validated robust coexpression
of CD41 in CD31+ endothelium of control but notScl/ yolk sacs
(Figure 1E). These data indicate that Scl activates a network of
hematopoietic transcription factors necessary for hemogenic
competence in the endothelium.
Loss of Scl Provokes Ectopic Cardiogenesis
in Hemogenic Tissues
To evaluate whether Scl has a repressive function in the endo-
thelium in hemogenic tissues, GO enrichment analysis was
performed for the 965 genes upregulated in CD31+ cells in
Scl/ yolk sacs. Unexpectedly, several highly significant GO
categories were related to cardiogenesis and heart function (Fig-
ure 2A). The upregulated genes included key cardiac transcrip-
tion factors such as Isl1, Myocd, Smarcd3, and Tbx5, as well
as several cardiomyocyte-specific structural proteins including
Tnnt2, Myl7, Actc1, Myh6, Myh7, and Ryr2 (Figure 2A; Table
S1b). qPCR analysis confirmed ectopic expression of cardiac
genes in Scl/ yolk sacs (Figure 2B), while fluorescence-
activated cell sorting (FACS) documented a population of cells
expressing Troponin T (data not shown). IF revealed frequent
coexpression of Troponin I (9.0 ± 4.5%) or T (19.5 ± 0.5%) in
CD31+ cells in Scl/ yolk sacs (Figure 2C), and whole mount
staining identified clusters of ectopic cardiomyocytes scattered
throughout the yolk sac (Figure 2D). Furthermore, explant
cultures of Scl/ yolk sacs produced colonies of synchronously
beating cardiomyocytes (Movies S1A and S1B; Figure 2E).
Formation of beating colonies from Scl/ yolk sacs was highly
reproducible (26/28), and, in some cases, individual beating cells
were observed after as few as 4 hr in culture, indicating that
ectopic cardiomyocytes had matured in situ (Movie S1C). Cardi-
omyocytes from Scl/ yolk sacs evidenced spontaneous
calcium transients, which could be inhibited by the calcium
channel blocker nifedipine. Moreover, ectopic cardiomyocytestic transcription factors (TFs) and other proteins significantly downregulated
CD41+cKit+ HS/PCs is shown for comparison. Selected GO categories derived
ogical replicates normalized to HPRT is shown.
n, single channel + DAPI images of boxed areas. Scale bar, 25 mm. In all panels,
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were capable of storing Ca2+ within the sarcoplasmic reticulum,
which was susceptible to caffeine-induced release (Figure 2F).
These results demonstrate that Scl is critical for suppressing
cardiomyogenesis in the yolk sac.
Scl Activates Hematopoiesis and Represses
Cardiogenesis in Placental Vasculature
To investigate if Scl also modulates endothelial fate in other
hematopoietic tissues, we performed microarray analysis on
CD31+ cells in the placenta, another site that can generate
multipotent HS/PCs (Rhodes et al., 2008; Zeigler et al., 2006).
These results verified that also in placental endothelium, Scl
activatesmany of the same hematovascular transcription factors
as in the yolk sac, with the addition of Sox17 and Bmi1 that
regulate self-renewal of fetal and adult HSCs (Kim et al., 2007;
Park et al., 2003) (Table S2a). No significant expression of
cardiac structural proteins was detected in Scl/ placental
endothelium; however, there was expression of transcription
factors essential for cardiac progenitor cell function including
Isl1 and Smyd1, as well as cardiac morphogenesis genes
including Has2, Dkk1, and Vcan (Figures S1B and S1C; Table
S2b). These results indicate that the misspecification of
prospective hemogenic endothelium to the cardiac fate is not
limited to the yolk sac.
Loss of Scl Leads to the Emergence of CD31+Pdgfra+
Cardiogenic Cells from Prospective Hemogenic
Endothelium
To identify the cardiogenic cells in the vasculature, we screened
the microarray data for surface proteins upregulated in Scl/
endothelium in both the yolk sac and the placenta. Pdgfra, a
marker of cardiogenic mesoderm (Kattman et al., 2011), was
significantly upregulated in Scl/ endothelium in both tissues
(Figure 2A; Figure S1C). FACS analysis of E 9.25 conceptuses
identified a subpopulation of CD31+ cells coexpressing Pdgfra
in all hematopoietic tissues in Scl/ embryos (Figure 3A). By
E 8.5, CD31+Pdgfra+ cells had already formed in the Scl/
yolk sac but were just emerging in the placenta (Figure S2A).
CD31+Pdgfra+ cells were not found in hematopoietic tissues in
controls (Figure 3A), even at an earlier developmental stage
(Figure S2A).
Microarray analysis comparing CD31+Pdgfra endothelial
cells and CD31+Pdgfra+ putative cardiogenic cells from Scl/
yolk sacs revealed upregulation of cardiac transcription factors
and structural proteins in CD31+Pdgfra+ cells (Figure 3B;Figure 2. Lack of Scl Induces Cardiomyogenesis in YS Vasculature
(A) Selected GO categories encompassing genes upregulated in Scl/ YS en
change of known cardiac TFs and other proteins significantly upregulated (>1.5-f
shown for comparison.
(B) qPCR for cardiac TFs and cardiomyocyte structural genes on E 9.25 unfracti
(C) IF for Troponin I (n = 2; Troponin T, n = 3) and CD31 on YS sections; insets are
25 mm.
(D) Whole mount IF for Troponin T on YSs. Scale bar, 50 mm.
(E) Frequency of YSs generating beating colonies in explant culture (see Movie S
(F) Scl/ YS explants were loaded with Fluo4-AM and spontaneous calcium
and caffeine (10 mM) were added at the indicated times. In all panels, error bars
See also Figure S1, Tables S1B and S2B, and Movie S1.
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Flk1, Esam1,Cdh5/Ve-cadherin, etc.) was downregulated (Table
S3b; Figures S2B and S2C). qPCR for Isl1 and Gata6 on sorted
cells from the yolk sac and the placenta confirmed the upregula-
tion of cardiac transcription factors in CD31+Pdgfra+ cells
(Figure 3C). The head endothelium in Scl/ embryos neither
generatedCD31+Pdgfra+ cells (Figure 3A) nor expressed cardiac
transcription factors (Figure 3C). These data verify cardiac
identity of CD31+Pdgfra+ cells and suggest that the ectopic
cardiogenesis in Scl/ embryos is restricted to a specific type
of endothelium.
Of note, comparison of gene expression in CD31+Pdgfra
endothelial cells between Scl/ and control yolk sacs revealed
that the cardiogenic transcriptional program was initiated in
endothelial cells (Figure S2D; Table S3c). Furthermore, IF for
CD31 and Pdgfra+ in Scl/ yolk sacs documented integration
of CD31+Pdgfra+ cardiogenic cells within the vasculature (Fig-
ure 3D). To functionally assess the developmental potential of
CD31+Pdgfra endothelium and CD31+Pdgfra+ cells in Scl/
embryos, we sorted these populations and plated them in
cardiac differentiation conditions. Both populations from Scl/
yolk sac had the potential to generate cardiomyocytes, as
evidenced by Troponin T expression, presence of organized
sarcomeres, and spontaneous beating (Figures 3E and S2E;
Movies S2A, S2B, S2C). Altogether, these data indicate that, in
the absence of Scl, endothelium in the yolk sac becomes
misspecified to cardiac fate.
The Requirement for Scl to Repress Cardiogenesis
in Hemogenic Tissues Is Cell Autonomous and
Temporally Defined
As the misspecified endothelium expressed both cell-intrinsic
(e.g., transcription factors) and secreted factors (e.g., Wnt
inhibitors Dkk1, Sfrp1, Sfrp5, and Frzb) that promote cardiac
differentiation, we asked if Scl acts cell autonomously to prevent
cardiogenesis in hematopoietic tissues and crossed tamoxifen-
inducible Rosa26Cre-ERT2 mice with Sclfl/fl mice (Figure 4A).
Injection of tamoxifen results in a peak of the active drug 12 hr
later, which facilitates nuclear localization of Cre (Zovein et al.,
2008). Injection of tamoxifen at E 6.5 did not result in a significant
difference in the hematopoietic compartment; however, CD31+
Pdgfra+ cardiogenic cells appeared in a majority of Rosa26-
Cre-ERT2Sclfl/fl yolk sacs (Figure 4B) and placentas (data not
shown). Coexistence of hematopoiesis and ectopic cardiomyo-
genesis in Rosa26Cre-ERT2Sclfl/fl yolk sacs was verified bydothelium are shown. Heat maps represent the relative expression and fold
old, p < 0.05) in Scl/ versus control YS CD31+ cells. CD41+cKit+ HS/PCs are
onated YSs; mean of four biological replicates normalized to HPRT is shown.
higher magnification, single channel + DAPI images of boxed areas. Scale bar,
1).
transients were measured using confocal microscopy. Nifedipine (10 mM)
represent SEM.
Figure 3. Scl Represses the Development of CD31+Pdgfra+ Cardiac Cells in Hemogenic Tissues
(A) FACS on cells depleted for CD41, CD45, and Ter119 showing CD31+Pdgfra+ cells (orange gates) and CD31+ endothelial cells (green gates) in embryonic
tissues (PL, placenta; pSP, para-aortic splanchnopleura; HD, head). Mean ± SEM of at least three biological replicates is shown.
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qPCR (Figure 4C). Although the deletion at the Scl locus in
Rosa26Cre-ERT2Sclfl/fl yolk sacs was only partial, PCR for
sorted CD31+Pdgfra+ cardiogenic cells demonstrated full
excision of both targeted alleles (Figure 4D). These data verify
a cell-intrinsic requirement for Scl in repressing ectopic
cardiogenesis.
To investigate whether the requirement for Scl to repress
the cardiomyogenesis continues after mesodermal fates
have diverged, we initiated injection at E 7.5 and the embryos
were harvested at E 10.5. In spite of later deletion, manyRosa26-
Cre-ERT2Sclfl/fl yolk sacs still generated CD31+Pdgfra+ cells
(Figure 4E) and expressed cardiac transcription factors and
structural proteins (Figure 4F). CD31+Pdgfra+ cells were
also observed in 2/8 placentas (data not shown). However,
when the deletion was induced a day later, at E 8.5, cardiac
conversion was no longer observed despite comparable
excision efficiency (Figures 4G and 4H; data not shown).
These data suggest that Scl is required for the repression of
the cardiac fate in hemogenic tissues for a limited developmental
window.
Scl Inhibits Cardiomyocyte Differentiation in the
Endocardium
As the loss of Scl induced ectopic cardiogenesis from endothe-
lium in hematopoietic tissues, we next examined Scl/ hearts
for evidence of endothelial misspecification. The heartbeat was
initiated in Scl/ hearts despite structural defects and pericar-
dial effusion (Figure 5A; data not shown). Scl/ outflow tracts
and right ventricles were hypomorphic compared to the left
ventricle, and the atrial and ventricular septa were poorly formed.
Moreover, the heart chambers were filled with poorly organized
endocardium (Figures 5A and 5B). IF for CD31 and Troponin T
revealed that a substantial population (16.7 ± 3.8%) of endocar-
dial cells coexpressed cardiomyocyte-specific proteins (Fig-
ure 5B), demonstrating misspecification of Scl/ endocardium
to cardiomyocytic fate.
Notably, CD31+Pdgfra+ cells were found in both Scl/ and
control hearts, although they emerged earlier (E 8.5) and were
more frequent (E 9.25) in Scl/ hearts (Figure 5C). Microarray
analysis of CD31+Pdgfra and CD31+Pdgfra+ cells from control
and Scl/ hearts revealed upregulation of the cardiomyogenic
transcriptional program in both Scl/ endocardium and
CD31+Pdgfra+ cells (Figures 5D and 5E; Table S4). In functional
assays, both the endocardium and CD31+Pdgfra+ cells from
Scl/ hearts generated beating cardiomyocytes that expressed
Troponin T and displayed organized sarcomeres (Movies S3A,
S3B, and S3C; Figure 5F). These data indicate that Scl
suppresses cardiomyocyte differentiation of endocardium and
CD31+Pdgfra+ cells in the heart.(B) Gene expression analysis of CD31+Pdgfra/CD31+Pdgfra+ cells from Scl/ Y
enriched in CD31+Pdgfra+ cells with their fold changes, as well as selected GO c
(C) qPCR for cardiac TFs on indicated populations sorted from YS, PL, and HD; un
replicates from pooled samples normalized to actin is shown.
(D) IF for CD31 and Pdgfra on YS sections (n = 3; mean ± SEM is shown). Scale
See Movie S2.
(E) CD31+Pdgfra+ cells were sorted from E 8.5 Scl/ YSs, cultured and stained
See also Figure S2, Table S3, and Movie S2.
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Fate Extends Perinatally in the Heart
We next assessed whether the timing when Scl is required to
suppress cardiomyocyte differentiation in the heart correlates
with that in hemogenic tissues (Figure S3A). When induction
was initiated at E 6.5 and embryos harvested at E 9.5, the
expression of cardiac structural proteins (e.g., Myl7) was signif-
icantly increased in both CD31+Pdgfra- endocardial cells and
CD31+Pdgfra+ cells in Rosa26Cre-ERT2Sclfl/fl embryos (Fig-
ure S3B). Upregulation of Myl7 was also observed in CD31+
Pdgfra+ cells in Rosa26Cre-ERT2Sclfl/fl hearts upon later induc-
tion at E 8.5 or 16.5 (harvest at E 11.5 and 19.5, respectively),
after cardiogenic potential in the yolk sac had subsided (Figures
S3C and S3D). Remarkably, in some cases, sorted CD31+
Pdgfra+ cells from Rosa26Cre-ERT2Sclfl/fl perinatal hearts
(E 19.5) generated spontaneously beating Troponin T+ cardio-
myocytes (Figure S3D and Movie S4). These data indicate that
the requirement for Scl to repress the cardiomyocyte fate con-
tinues perinatally in CD31+Pdgfra+ cells in the heart (Figure S3E).
CD31+Pdgfra+ Putative Cushion Mesenchymal Cells
Emerge from Ve-cadherin+Isl1+ Precursors during
Normal Development
As the requirement to repress cardiomyocyte differentiation in
the later heart became confined to CD31+Pdgfra+ cells, we
sought to define their identity and origin. CD31+Pdgfra+ cells in
control hearts appeared first by E 9.25; their frequency peaked
at around E 10.5 and then declined, although a small population
persisted until early postnatal life (Figure S4A). IF demonstrated
that CD31+Pdgfra+ cells in control hearts at E 9.5 were localized
specifically to the outflow tract (OFT) and the atrioventricular
canal (AVC) (Figure S4B), in contrast to Scl/ hearts where
CD31+Pdgfra+ cells were found throughout the heart (data not
shown). Microarray analysis showed that theCD31+Pdgfra+ cells
in normal hearts were enriched for cardiac transcription factors
Smarcd3, Hand1, Gata4, and Gata6 (Figure S4C; Tables S4e
and S4f) and expressed several transcription factors associated
with EMT (epithelial-mesenchymal transition) including Twist1,
Snai1, Twist2, and Zeb2. Furthermore, several genes involved
in endocardial cushion morphogenesis, including Erbb3, Sox9,
Msx1, Tgfb2, andVcan, were upregulated in CD31+Pdgfra+ cells.
Based on the timing when CD31+Pdgfra+ cells were found in
normal hearts, their localization in the OFT and AVC, and gene
expression, we concluded that this population contains precur-
sors of cardiac cushion mesenchymal cells.
We next investigated whether the CD31+Pdgfra+ cells in the
heart have similar lineage relationship with endothelial cells as
HS/PCs in hemogenic tissues and performed lineage tracing
using the endothelial Ve-cadherin Cre strain bred to theSs. Differentially expressed (>1.5-fold, p < 0.05) cardiac TFs, and other proteins
ategories, are shown.
fractionated heart (HT) was used as a positive control. Mean ± SD of technical
bar, 25 mm.
for Troponin T. Scale bar, 25 mm.
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Rosa26-YFP reporter strain (Figure S4D) (Alva et al., 2006;
Stadtfeld and Graf, 2005). In the heart, both CD31+Pdgfra- endo-
thelial cells as well as CD31+Pdgfra+ cushion mesenchymal cells
evidenced equally efficient marking by the Ve-cadherin Cre
(Figure S4D), although the latter had downregulated endothelial
genes (Figure S4E). The efficiency of lineage tracing in placental
and yolk sac endothelium and circulating HS/PCs was similar to
that observed in the heart (data not shown). These results further
strengthen the hypothesis that CD31+Pdgfra+ cells represent
cushion mesenchymal cells, which are derived from endocar-
dium (de Lange et al., 2004). Furthermore, lineage tracing using
Isl1 Cre (Cai et al., 2003)—a transcription factor regulating multi-
potent cardiac progenitors (Moretti et al., 2006)—revealed that
a large fraction of the endocardium andCD31+Pdgfra+ cells orig-
inate from Isl1+ precursors (Figure S4F). Moreover, analysis of
Isl1/ hearts revealed that the establishment of CD31+Pdgfra+
cells was Isl1 dependent (Figure S4G). These data suggest that
CD31+Pdgfra+ cells in the wild-type heart represent cushion
mesenchymal cells and are distinct from the ectopic cardiomyo-
genic CD31+Pdgfra+ cells in Scl/ hearts.
Runx1 and Isl1 Do Not Have a Critical Effect on Cardiac
Misspecification of Endothelium
To understand the mechanisms downstream of Scl that modu-
late hematopoietic versus cardiac development in the endothe-
lium, we asked if the emergence of CD41+cKit+ HS/PCs or
CD31+Pdgfra+ cardiogenic cells was dependent on known
HS/PC or cardiac progenitor transcription factors that Scl regu-
lates. Analysis of Runx1/ embryos verified that the emergence
of HS/PCs from hemogenic endothelium was Runx1 dependent
(Figure 6A). However, in contrast to Scl/ embryos, no CD31+
Pdgfra+ cells were detected in hematopoietic tissues in
Runx1/ embryos, nor was this population expanded in the
heart (Figures 6B and 6C). Lack of ectopic cardiac differentiation
in Runx1/ yolk sacs was further confirmed by qPCR (Fig-
ure 6E). These results imply that, despite its pivotal role in the
transition of hemogenic endothelium to HS/PCs, Runx1 is not re-
quired to repress cardiac conversion of endothelium (Figure 6F).
As Isl1/ embryos showed a drastic reduction of CD31+
Pdgfra+ cells in the heart (Figure S4G), we asked whether gener-
ation of cardiogenic CD31+Pdgfra+ cells in Scl/ embryos was
also dependent on Isl1 and generated Scl/Isl1/ embryos.
Morphologically, Scl/Isl1/ embryos evidenced a compound
phenotype with absence of blood, smaller embryonic size, and
lack of pharyngeal arches and cardiac outflow tract (Figure 6D).
It is interesting that CD31+Pdgfra+ cells were generated in the
yolk sac and the heart of Scl/Isl1/ embryos, and cardiac
transcription factors and structural proteins, including Gata6,
Smarcd3, Myocd, Tnnt2, and Myl7, were ectopically expressedFigure 4. Scl Has a Cell-Autonomous, Temporally Defined Role in Prev
(A) Tamoxifen-inducible Rosa26Cre-ERT2 mouse strain was used to delete Scl a
(B, E, and G) FACS for CD41+cKit+ HS/PCs (red ovals) and Ter119+ RBCs (purple
dams injected at E 6.5 (B), E 7.5 (E), and F 8.5 (G). Analysis for CD31+ cells (g
frequencies of HS/PCs, RBCs, and CD31+Pdgfra+ cells in individual embryos.
(C, F, and H) qPCR for cardiac and/or hematopoietic genes on YSs following inje
normalized to HPRT in individual embryos. (D) PCR of embryonic head DNA (le
CD31+Pdgfra versus CD31+Pdgfra+ cells sorted from Rosa26Cre-ERT2Sclfl/fl YS
598 Cell 150, 590–605, August 3, 2012 ª2012 Elsevier Inc.(Figure 6E). These data indicate that cardiac conversion in
Scl/ endothelium is independent of Isl1 (Figure 6F).
Cardiomyocyte Differentiation from Endothelium
Is Promoted by Wnt Antagonism
Wenext sought to define themechanisms that promote the rapid
cardiomyocyte differentiation in the endothelium of Scl/ yolk
sacs and hearts. Notably, expression of cardiac transcription
factors Isl1 and Tbx5, as well as structural proteins Myl7 and
Tnnt2, were induced in Scl/ yolk sacs by E 8.5, concurrent
with the appearance of CD31+Pdgfra+ cells (Figures 7A and
S2A). Likewise, expression of several canonical Wnt antagonists
including Dkk1, Frzb, Sfrp1, and Sfrp5 that promote terminal
cardiomyocyte differentiation (David et al., 2008; Jaspard
et al., 2000; Schneider and Mercola, 2001) was also observed
at E 8.5 (Figure 7B).We therefore askedwhetherScl/ endothe-
lial cells respond to Wnt inhibition. Indeed, gene set enrichment
analysis (GSEA) comparing Scl/ yolk sacs with expression
data from differentiating mouse embryoid bodies treated with
the Wnt inhibitor Dkk1 (Lindsley et al., 2008) revealed a highly
significant correlation of gene expression, indicating that Scl/
endothelial cells are responding to canonical Wnt inhibition
(Figure 7C). Similar correlations were also observed in the heart
and the placenta (Figures S5A and S5B).
As Wnt inhibitors are known to promote differentiation of
cardiac cells, we asked if the ectopic cardiogenic cells in Scl/
tissues respond to Wnt agonists to preserve a more undifferen-
tiated state. Pregnant dams carrying Rosa26Cre-ERT2Sclfl/fl
embryos were first injected with tamoxifen at E 6.5 to induce
cardiogenic conversion and subsequently stimulated by the
Wnt agonist LiCl, or control NaCl, after which yolk sacs were as-
sayed for cardiomyocyte gene expression at E 11.5. qPCR re-
vealed that the expression of cardiac structural proteins Myl7
and Tnnt2 was significantly reduced upon Wnt stimulation (Fig-
ure 7D). Moreover, when Scl/ yolk sacs were plated in explant
culture and supplemented either with LiCl or NaCl throughout the
9 to 10-day culture, the colonies containing beating cardiomyo-
cytes were larger and their size continued to increase over
several days upon Wnt stimulation (Figure 7E). These results
indicate that, in vivo, Scl/ ectopic cardiogenic precursors
experience Wnt antagonism that promotes cardiomyocyte
differentiation; however, at least a subset of these cells retain
the capacity to respond to Wnt stimulation (Figure 7F).
DISCUSSION
Our work has uncovered unexpected cardiogenic potential in
prospective hemogenic endothelium in blood-forming tissues
and endocardium in the heart. Upon loss of a single transcriptionenting Ectopic Cardiogenesis in Hemogenic Tissues
t desired time points.
circles) in Rosa26Cre-ERT2Sclfl/+ and Rosa26Cre-ERT2Sclfl/fl YSs of pregnant
reen ovals) and CD31+Pdgfra+ cells (orange circles) is shown. Graphs show
ction at E 6.5 (C), E 7.5 (F), and (H) E 8.5. Graphs show mRNA expression level
ft) isolated from embryos injected at E 6.5 and harvested at E 9.5. PCR from
s (right).
Figure 5. Scl/ Endocardium Is Misspecified to Cardiomyogenic Fate
(A) Scl/ hearts evidenced malformed outflow tract (dotted lines) and pericardial effusion (arrow).
(B) IF for CD31 and Troponin T on heart sections (n = 3; mean ± SEM is shown). Scale bar, 25 mm.
(C) FACS for CD31+ endocardial cells (green ovals) and CD31+Pdgfra+ cells (orange circles) in the heart at E 8.5 and E 9.25.Mean ±SEMof at least three biological
replicates is shown.
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factor, Scl, endothelium in these tissues gives rise to cardiogenic
precursors that differentiate into spontaneously beating
cardiomyocytes. The temporal window when Scl is required to
repress cardiomyogenesis in hematopoietic tissues closely
parallels the timing of HS/PC specification in hemogenic endo-
thelium, while in the heart, the repressive function of Scl
continues perinatally in CD31+Pdgfra+ putative cushion mesen-
chymal cells. Previous studies had suggested that Scl hasmeso-
derm patterning activity during early development, as overex-
pression of Scl in mesoderm during embryonic stem cell
differentiation promoted hematopoiesis at the expense of
cardiac and paraxial mesoderm (Ismailoglu et al., 2008). Like-
wise, modulation of Scl and Etsrp (zebrafish homolog for Etv2/
ER71) expression altered the size of the heart field (Schoenebeck
et al., 2007), and loss of Etsrp/Etv2 induced cardiomyocyte gene
expression in endocardial progenitors (Palencia-Desai et al.,
2011; Rasmussen et al., 2011). These studies delineate a critical
function for Scl and its upstream regulator Etsrp/Etv2 in
promoting hematovascular fates over cardiac potential during
mesoderm specification. Nevertheless, our finding that loss of
Scl in the endothelium in hemogenic tissues and the heart after
mesodermal tissues have diverged can give rise to fully func-
tional, beating cardiomyocytes reveals unforeseen develop-
mental plasticity in embryonic endothelium and identifies Scl
as a master regulator of endothelial fate choice.
Developmental fate decisions require precise orchestration
of both cell-intrinsic and microenvironmental regulatory mecha-
nisms. Modulation of Wnt signaling has pivotal effects at
multiple stages of cardiac mesoderm and progenitor cell devel-
opment: Wnt antagonists induce cardiac specification from
mesoderm and promote cardiomyocyte differentiation
(Schneider and Mercola, 2001; Ueno et al., 2007), while activa-
tion of canonical Wnt signaling expands cardiac progenitors
and maintains them in an undifferentiated state (Qyang et al.,
2007). Our study suggests that ectopic cardiomyogenic cells
progress through a Wnt-responsive precursor state, the differ-
entiation of which is promoted by Wnt antagonists. Neverthe-
less, our finding that cardiac conversion was cell intrinsic to
loss of Scl, and could not be induced solely by secretion of
Wnt inhibitors by neighboring Scl/ cells, is in an agreement
with the notion that morphogen-induced mesoderm patterning
requires relatively uncommitted cells. Recent studies have
documented conversion of other mesodermal tissues to cardio-
myocytes in vitro and in vivo by reprogramming with a combina-
tion of cardiac transcription factors (Gata4, Tbx5, Smarcd3, and/
or Mef2c) (Ieda et al., 2010; Qian et al., 2012; Takeuchi and
Bruneau, 2009); the same factors were also induced in Scl/
yolk sac endothelial cells. Our data document that an altered
cell-intrinsic regulatory program caused by loss Scl is sufficient
to override the microenvironmental cues that dictate meso-
dermal fate.(D) Gene expression analysis of Scl/ and control CD31+Pdgfra- endocardial ce
and their fold changes, as well as selected GO categories enriched in Scl/ CD
(E) Gene expression analysis of Scl/ and control CD31+Pdgfra+ cells from the he
and their fold changes, as well as selected GO categories enriched in Scl/ CD
(F) IF for Troponin T on cells derived from E 8.5 Scl/ CD31+Pdgfra/CD31+Pdg
See also Figures S3 and S4, Table S4, and Movies S3 and S4.
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AVC in normal hearts, their gene expression (cardiac transcrip-
tion factors and genes related to EMT) and endothelial origin,
we proposed that these cells represent cushion mesenchymal
cells, which give rise to the septa and valves (Yamagishi et al.,
2009). Thus, our data not only identify markers to enrich putative
cushion mesenchymal cells, but also uncover a requirement for
Scl to suppress cardiomyocyte differentiation in this endothe-
lial-derived precursor. Moreover, analysis of Isl1/ embryos
revealed a role for Isl1 in CD31+Pdgfra+ cushion mesenchymal
cells. As Isl1 is required for the development of both the multipo-
tent cardiac progenitors and CD31+Pdgfra+ cushion mesen-
chymal cells, it was surprising that the ectopic CD31+Pdgfra+
cells in Scl/ yolk sacs or hearts were not dependent on Isl1
for their generation. These data indicate that, despite a similar
surface phenotype, the CD31+Pdgfra+ cells in control hearts
and Scl/ tissues represent different cells with distinct develop-
mental potential, localization, and regulation. Our data suggests
that loss of Scl triggers a rapid differentiation program in the
endothelium/endocardium that makes ectopic cardiogenesis
independent of Isl1.
This work has revealed a broader than anticipated potential
for embryonic endothelium as a prospective source of multiple
mesodermal stem/progenitor cells, introducing the concept
of ‘‘cardiogenic endothelium.’’ Our data revealed that endothe-
lium with cardiomyogenic potential emerges in Scl/ embryos
in both hemogenic tissues as well as the heart, but not in nonhe-
mogenic head endothelium, implying specificity of latent cardio-
genic potential to a unique subset of endothelium. Furthermore,
our finding about the distinct temporal windows when cardio-
genic fate can be induced in hemogenic endothelium, endocar-
dium, or CD31+Pdgfra+ putative cushion mesenchymal cells
opens up important future questions to define the mechanisms
that close the window of opportunity for cardiomyocyte develop-
ment in different tissues. These data also raise the questions
of to what extent can endothelial-derived cardiac cells contribute
to normal heart development or regeneration, and how could
modulation of Scl expression be exploited to improve the differ-
entiation of pluripotent stem cells or partially committed precur-
sors for therapeutic applications. These results call for future
studies to examine the prospect of harnessing the latent cardio-
genic potential in the vasculature for use in regenerative medi-
cine and to investigate whether similar developmental plasticity
exists in othermajor cell fate decisions in the developing embryo.
EXPERIMENTAL PROCEDURES
Mouse Models
Details about mouse models and genotyping can be found in Extended
Experimental Procedures. Mice were maintained according to the guidelines
of the University of California, Los Angeles (UCLA), Animal Research
Committee.lls. Differentially expressed (>1.5-fold, p < 0.05) cardiac TFs and other proteins
31+Pdgfra cells, are shown.
art. Differentially expressed (>1.5-fold, p < 0.05) cardiac TFs and other proteins
31+Pdgfra+ cells, are shown.
fra+ cells that were sorted and cultured Scale bar, 25 mm.
Figure 6. Runx1 and Isl1 Are Not Major Regulators of the Ectopic Cardiomyogenic Cells
(A–C) FACSwas performed on (A and B) YS and (C) hearts isolated from control,Scl/,Runx1/, Isl1/, and Scl/Isl1/ embryos. All p values shown are with
respect to control unless otherwise indicated. (A) CD41+cKit+ HS/PCs (red ovals) are shown in YS and CD31+Pdgfra+ cells (orange ovals) are shown in (B) YS and
(C) heart.
(D) Scl/Isl1/ embryos lacked blood in the YS (arrows, left panels), pharyngeal arches (arrowheads, left panels), and outflow tract (circles, left panels).
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FACS Analysis and Isolation of HS/PCs, Endothelial Cells, and
Cardiac Cells
Cells from embryonic tissues were isolated as described elsewhere
(Rhodes et al., 2008). For details about FACS, see Extended Experimental
Procedures.
Differential Gene Expression Analysis
RNA was isolated using the RNeasy Micro kit (QIAGEN), amplified using the
NuGEN Pico kit, and hybridized on Affymetrix Mouse Genome 430 2.0 Array
GeneChip microarrays (GEO Accession Number GSE27445). For details on
how differentially expressed genes were identified, analyzed and verified,
see Extended Experimental Procedures.
Analysis of Tissue Sections and Whole Mounts by Confocal
Microscopy
Fixed frozen sections were prepared and stained as described elsewhere
(Rhodes et al., 2008), with the same antibodies used in FACS, Troponin I
(1:400, Santa Cruz) or cardiac Troponin T (1:400, Sigma). Whole mount yolk
sacs were prepared as described elsewhere (Ahnfelt-Ronne et al., 2007) and
stained for Troponin T. Confocal images were obtained on a Zeiss LSM 510
equipped with 405 nm, 488 nm, 543 nm, and 633 nm lasers. Images were pro-
cessed with ImageJ software (National Institutes of Health [NIH]).
Cardiac Culture Assays
Yolk sacs were mechanically dissociated by pipetting or enzymatically
dissociated, sorted, and plated on OP9 stromal cells in cardiac medium
(a-minimum essential medium with 20% fetal bovine serum, 5 ng/ml murine
vascular endothelial growth factor, 50 ng/ml human bone morphogenetic
protein 4, and 30 ng/ml human basic fibroblast growth factor; Peprotech)
or directly on Matrigel and fibronectin-coated chamber slides (BD Biosci-
ences) with or without 1 mM XAV939 (Wnt antagonist; Sigma), 2 mM LiCl
(Wnt agonist), or 2 mM NaCl (control). Videos were taken with a Nikon Diaphot
300 microscope and XY Clone software (Hamilton Thorne Biosciences).
Analysis of beating area was performed using VirtualDub software (v1.9.11)
and ImageJ (NIH).
Measurement of Calcium Transients
Yolk sacs were cultured on petri dishes (MatTek Corporation) coated with Ma-
trigel in cardiac medium for 9–10 days. Before imaging, explants were loaded
with the Ca2+-sensitive dye Fluo-4AM (Molecular Probes) in the presence of
Pluronic F-127 (Molecular Probes). Spontaneous transients were imaged on
a Zeiss LSM 5 Pascal confocal microscope equipped with a 488 nm laser.
In Vivo Manipulation of Regulation
Scl deletion in Rosa26Cre-ERT2Sclfl/fl embryos was induced by Tamoxifen
(Sigma Aldrich T5648) or (Z)-4-hydroxytamoxifen (Sigma Aldrich H7094).
Tamoxifen was suspended at 100 mg/ml in ethanol and mixed with sesame
oil at a final concentration of 10 mg/ml (10% ethanol). Pregnant females
were injected i.p. with 125 ml tamoxifen at the indicated days. Injections of
250 mg/kg NaCl and LiCl (Wnt agonist) were performed as described (Tian
et al., 2010).
Statistical Analysis
For statistical analysis, Student’s unpaired two-tailed t test was used for all
comparisons.
ACCESSION NUMBERS
For all array data, GEO Accession Number GSE27445 is given earlier, within
the Experimental Procedures.(E) qPCR for hematopoietic and cardiac TFs and cardiomyocyte structural genes o
replicates normalized to HPRT are shown.
(F) Runx1 and Isl1 are required for HS/PC generation and cardiac cushion devel
panels, error bars represent SEM.
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